الفهرس 
Etiology and PathophysiologyOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Whole-body imaging is increasingly successfully applied in MRI imaging, especially in staging of lymphoma
the field of systemic malignant diseases affecting the bone and in diseases predisposing to malignant transformation. Whole-body MRI is able to depict bone marrow pathologies with high resolution and excellent soft tissue contrast by demonstrating signal alterations due to changes in its fat, water, and hematopoietic cell components with high resolution and excellent soft tissue contrast. Together
with CT or PET-CT and its valuable additional metabolic information, it has great potential in the more
comprehensive,more accurate, and earlier diagnosis of bone marrow infiltrative diseases.
Although further evaluation of the true potential of whole-body applications is awaited, they are promising tools aiding the more efficient management of
patients suffering from systemic malignant or benign diseases of the soft tissue and bone.
The main challenge facing oncologic imaging with PET/CT is the limited availability of new tracers to image
aspects of malignancy other than glucose utilization.
FDG is a nonspecific imaging agent of cancer, although it is useful for whole-body surveys to help stage disease. With a continuing progression toward the development of highly specific molecular tracers, the role of the PET/CT technology will increase .
whole-body MRI compared far more favorable than CT and 67Ga scan for detecting bone marrow lymphoma.
Further refinements in technique, including the use of contrast agents, may further improve the technique’s
accuracy.
PET/CT has recently emerged as a gold-standard test, and comparative tests between these two emerging techniques would be useful. For young patients in particular, in whom extensive longitudinal follow-up is anticipated,